AstraZeneca has reported a net profit of $1.92bn, or $1.24 per diluted share, for the second quarter ended 30 June 2024, a 6% rise compared to $1.82bn, or $1.17 per diluted share, for the respective period of the previous year.
The British drugmaker’s net profit for the second quarter of 2024 (Q2 2024) declined by 12% compared to $2.18bn for the first quarter of 2024 (Q1 2024)
The company reported total revenues of $12.93bn for Q2 2024, a 13% increase compared to $11.41bn for the same quarter in 2023, and a 2% rise compared to $12.67bn for Q1 2024.
AstraZeneca has reported an operating profit of $2.74bn for Q2 2024, a 12% increase compared to $2.45bn for the respective quarter in 2023.
The pharmaceutical company reported a profit before tax of $2.39bn for Q2 2024, a 15% rise compared to $2.08bn for the same period the previous year.
AstraZeneca CEO Pascal Soriot said: “Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS.
“At our Investor Day in May, we set out a new revenue ambition to deliver $80billion of Total Revenue by 2030. This is a clear reflection of the substantial growth potential we see from both our approved medicines and those in our late-stage pipeline.
“Already this year we have announced five positive, potentially practice-changing Phase III studies that are anticipated to meaningfully contribute to our growth.”
AstraZeneca has reported a net profit of $4.10bn, or $2.65 per diluted share, for the six months ended 30 June 2024, a 13% rise compared to $3.62bn, or $2.34 per diluted share, for the respective period in 2023.
The British drugmaker reported total revenues of $25.61bn for the first half of 2024 (H1 2024), a 15% increase compared to $22.29bn for the same period in the previous year.
The pharmaceutical company reported an operating profit of $5,861 for H1 2024, a 17% rise compared to $5,005 for the respective period in 2023.
AstraZeneca reported a profit before tax of $5.19bn for H1 2024, a 19% increase compared to $4.35bn for the same period in the previous year.
